Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00045435 |
Recruitment Status
:
Active, not recruiting
First Posted
: January 27, 2003
Results First Posted
: March 16, 2017
Last Update Posted
: May 19, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia in Remission Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Secondary Acute Myeloid Leukemia | Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation Drug: fludarabine phosphate Radiation: total-body irradiation Drug: cyclosporine Drug: mycophenolate mofetil Procedure: peripheral blood stem cell transplantation | Phase 2 |
PRIMARY OBJECTIVES:
I. To determine if a one-year disease free survival of >= 35% can be achieved among patients >= 55 years old with de novo and secondary AML in first complete remission (CR1) who undergo nonmyeloablative hematopoietic stem cell transplant (HSCT) from human leukocyte antigen (HLA) identical related donors.
II. To determine if a day +200 nonrelapse related mortality of < 15% can be achieved among patients >= 55 years old with de novo and secondary AML in CR1 who undergo nonmyeloablative HSCT from HLA identical related donors.
OUTLINE:
CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously (IV) on days -4 to -2 and undergo TBI on day 0.
TRANSPLANT: Patients undergo allogeneic PBSC transplant on day 0.
IMMUNOSUPPRESSION: Patients receive cyclosporine (CSP) orally (PO) twice daily (BID) on days -3 to 56 with taper to day 77. Patients also receive mycophenolate mofetil (MMF) PO BID on days 0-27.
After completion of study treatment, patients are followed up on days 28, 56, and 84; months 6, 12, 18, and 24; and then yearly for 5 years.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 17 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation From HLA Matched Related Donors for Treatment of Older Patients With De Novo or Secondary Acute Myeloid Leukemia in First Complete Remission |
Study Start Date : | April 2002 |
Actual Primary Completion Date : | June 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (nonmyeloablative donor PBSC transplant)
CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0. TRANSPLANT: Patients undergo allogeneic PBSC transplant on day 0. IMMUNOSUPPRESSION: Patients receive CSP PO BID on days -3 to 56 with taper to day 77. Patients also receive MMF PO BID on days 0-27. |
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Undergo nonmyeloablative allogeneic PBSC transplant
Drug: fludarabine phosphate
Given IV
Other Names:
Radiation: total-body irradiation
Undergo TBI
Other Name: TBI
Drug: cyclosporine
Given PO
Other Names:
Drug: mycophenolate mofetil
Given PO
Other Names:
Procedure: peripheral blood stem cell transplantation
Undergo nonmyeloablative allogeneic PBSC transplant
Other Names:
|
- Disease-free Survival-incidence of Survival Without Relapse [ Time Frame: By 1 year after transplant ]Sufficient evidence will be taken to be an observed rate of DFS at one year after transplant that corresponds to a one-sided 95% confidence interval with an upper limit lower than 35%.
- Nonrelapse Mortality (NRM)-Incidence of Nonrelapse Death [ Time Frame: 200 days after transplant ]Defined as death without morphologic evidence of disease. Sufficient evidence will be taken to be an observed rate of NRM within 200 days of transplant that corresponds to a one-sided 80% confidence interval with a lower limit greater than 15%.
- Overall Survival [ Time Frame: By 1 year after transplant ]Percent patients surviving.
- Incidence of Relapse [ Time Frame: By 1 year after transplant ]Percent patients with relapsed disease post-transplant.
- Incidence of Rejection [ Time Frame: By 1 year after transplant ]Percent patients who developed infections post-transplant.
- Incidence of Acute and Chronic GVHD [ Time Frame: aGVHD: 100 days after transplant; cGVHD: 1 Year after transplant. ]Percent patients with acute/chronic GVHD

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 55 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with de novo AML (French-American-British [FAB] MO-M2, M4-M7) or secondary AML who achieve CR1 after induction chemotherapy and one or two cycles of consolidation chemotherapy
- Transplant conditioning must occur within 6 months of diagnosis
- Patient enrollment must be approved by the Fred Hutchinson Cancer Research Center (FHCRC) principal investigator (PI) or the PI's designee
- DONOR: Related donor who is genotypically or phenotypically identical
- DONOR: Age >= 12 years
- DONOR: Donor must consent to filgrastim (G-CSF) administration and leukapheresis
- DONOR: Donor must have adequate veins for leukapheresis or agree to placement of central venous catheter (femoral, subclavian)
Exclusion Criteria:
- AML FAB M3
- AML involvement of the central nervous system (CNS) as defined by a positive cytospin of cerebral spinal fluid at the time of enrollment
- Presence of circulating leukemic blasts (in the peripheral blood) detected by standard pathology
- Human immunodeficiency virus (HIV) seropositivity
- Fungal infections with radiographic progression after receipt of amphotericin B or active triazole for greater than one month
- Diffusion capacity of carbon monoxide (DLCO) corrected < 40%
- Total lung capacity (TLC) < 40%
- Forced expiratory volume in one second (FEV1) < 40% or requiring supplementary oxygen
- The FHCRC principal investigator of the study must approve enrollment of all patients with pulmonary nodules
- Cardiac ejection fraction < 40%
- Patients with clinical or laboratory evidence of liver disease would be evaluated for the cause of liver disease, its clinical severity in terms of liver function, bridging fibrosis, and the degree of portal hypertension; patients will be excluded if they are found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3mg/dL, or symptomatic biliary disease
- Karnofsky Performance Score < 70
- Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment
- Females who are pregnant or breastfeeding
- No intensive chemotherapy can be given within three weeks (or the interval in which a cycle of standard chemotherapy would be administered in a non-transplant setting) prior to initiating the nonmyeloablative transplant conditioning
- Patients with active non-hematologic malignancies (except non-melanoma skin cancers)
- Patients with a history of non-hematologic malignancies (except non-melanoma skin cancers) currently in a complete remission, who are less than 5 years from the time of complete remission, and have a > 20% risk of disease recurrence
- Patients with active bacterial or fungal infections unresponsive to medical therapy
- DONOR: Identical twin
- DONOR: Pregnancy
- DONOR: HIV seropositivity
- DONOR: Inability to achieve adequate venous access
- DONOR: Known allergy to G-CSF
- DONOR: Current serious systemic illness

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00045435
United States, Oregon | |
OHSU Cancer Institute | |
Portland, Oregon, United States, 97210 | |
United States, Washington | |
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | |
Seattle, Washington, United States, 98109 |
Principal Investigator: | Brenda Sandmaier | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium |
Responsible Party: | Brenda Sandmaier, Principal Investigator, Fred Hutchinson Cancer Research Center |
ClinicalTrials.gov Identifier: | NCT00045435 History of Changes |
Other Study ID Numbers: |
1654.00 NCI-2011-01307 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) |
First Posted: | January 27, 2003 Key Record Dates |
Results First Posted: | March 16, 2017 |
Last Update Posted: | May 19, 2017 |
Last Verified: | April 2017 |
Additional relevant MeSH terms:
Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Myelodysplastic Syndromes Preleukemia Neoplasm Metastasis Leukemia, Monocytic, Acute Leukemia, Myelomonocytic, Acute Leukemia, Megakaryoblastic, Acute Leukemia, Erythroblastic, Acute Neoplasms by Histologic Type Neoplasms Bone Marrow Diseases Hematologic Diseases Precancerous Conditions |
Neoplastic Processes Pathologic Processes Myeloproliferative Disorders Fludarabine Fludarabine phosphate Mycophenolic Acid Cyclosporins Cyclosporine Vidarabine Antineoplastic Agents Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors |